EC Number |
Inhibitors |
Structure |
---|
3.4.21.34 | 1-benzyl-1H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide |
ASP-440, small molecule inhibitor of plasma kallikrein |
|
3.4.21.34 | 2-mercaptoethanol |
inhibition of prekallikrein activation |
|
3.4.21.34 | 2-[3'-acetyl-5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6-hydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-2',6-dihydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-2'-fluoro-6-hydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-3',6-dihydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-3'-carbamoyl-6-hydroxybiphenyl-3-yl]butanedioic acid |
inhibitor with the best potency and selectivity profile for plasma kallikrein versus related serine proteases. This compound is highly stable in vivo and could be further developed for the treatment and inflammatory or coagulation disorders. Pharmacokinetic data |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-3'-chloro-6-hydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-3'-cyano-6-hydroxybiphenyl-3-yl]butanedioic acid |
- |
|
3.4.21.34 | 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-4'-chloro-6-hydroxybiphenyl-3-yl]butanedioic acid |
- |
|